<DOC>
	<DOCNO>NCT00487448</DOCNO>
	<brief_summary>Association group therapeutic speciality authorize remission induction treatment ( FLAG-IDA : fludarabine , cytarabine , G-CSF ( lenograstim ) idarubicin ) intensive postremission treatment authorize therapeutic association speciality with/without Autologous Hemopoietic Stem Cell Transplantation Bone Marrow Transplantation Patients With High Risk Myelodysplastic Syndromes Secondary Acute Myeloblastic Leukemia .</brief_summary>
	<brief_title>SMD_FLAG-IDA_98 : FLAG-IDA Induction Treatment High Risk Myelodysplastic Syndromes Secondary Acute Myeloblastic Leukemia</brief_title>
	<detailed_description>To reach first remission , patient receive one cycle FLAG-IDA combination , include : Fludarabine 30 mg/m 2 /d Days 1 4 IV perfusion 30 minute ; Cytarabine 2 g/m 2/d , day 1 4 IV perfusion 4 hour glycosylate G-CSF 300 µg/m 2/d , day -1 5 SC ; lenograstim 263 µg/d f , day 11 absolute neutrophil count &gt; 1x10 9 /L SC ; Idarubicin 10 mg/m2/d , day 1 3 IV bolus ( 15 minute ) Patients n't reach complete remission ( CR ) consider failure must go study . The participate centre decide patient 35 year CR unrelated donor , exclude treat allogenic transplantation continue study . The patient reach CR receive one consolidation cycle IDA-ARAC + G-CSF combination : Idarubicin 10 mg/m2/d , day 1 3 IV bolus ( 15 minute ) ; Cytarabine 200 mg/m 2/d day 1 5 IV 24 hour continuous perfusion ; glycosylate G-CSF ( lenograstim ) 263 µg , day 12 absolute neutrophil count &gt; 1x10 9 /L SC The patient young 65 year possible , do autologous transplantation peripheral stem blood cell combine peripheral stem blood cell bone marrow stem cell . The preparative regimen recommend BuCy2 ( busulfan-cyclophosphamide ) ICT-Cy ( irradiation corporal total-cyclophosphamide ) . The patient older 65 year receive one intensification cycle carboplatin G-CSF . The peripheral blood stem cell collection do recuperation period consolidation chemotherapy patient 65 year . The leucapheresis procedure could determinate center participate . The patient sufficient collection stem cell regeneration period post-chemotherapy consolidation , receive glycosylate G-CSF ( lenograstim , Granocyte® ) 10 µg/kg/d SC 5 day , collection cell day 5 6 . In situation peripheral blood stem cell non satisfactory , realize collection bone marrow stem cell . The realization Peripheral Blood Stem Cell Transplantation combine , depend number cell obtain collection procedures.In situation n't reach sufficient number cell ( peripheral blood bone marrow ) , administer one chemotherapy intensification cycle . The preparative regimen establish participate center , recommend one next : 1 . BuCy2 ( busulfan 16 mg/kg follow cyclophosphamide 120 mg/kg ) , 2 . Total-body irradiation 12 Gy cyclophosphamide 120 mg/kg . Intensification treatment : Patients older 65 year younger 65 collection cell transplantation enough , receive one cycle intensification chemotherapy carboplatin glycosylate G-CSF : Carboplatin 300 mg/m2/d day 1 4 IV 24 hour continuous perfusion glycosylate G-CSF ( lenograstim ) 263 µg f day 11 absolute neutrophil count &gt; 1x10 9 /L , SC</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Age &lt; 75 year Diagnosis Myelodysplastic Syndrome order FAB criterion , exclude patient chronic myeloid leukemia . IPI &gt; 1 ( High risk Intermedia risk2 ) and/or IPE equal &gt; 3 ( High risk Intermedia risk ) secondary acute myeloid leukemia . Resolved toxicity previous treatment receive Myelodysplastic Syndrome . Myelodysplastic Syndrome de novo . Associated neoplasia . Chronic disease limit patient follow protocol ( cardiovascular disease , active infection uncontrolled , etc. ) . Age &lt; 55 year related donor HLA compatible . Use investigational drug 30 previous day . Previous treatment chemotherapy agent . Simultaneous treatment study drug allow protocol . Bilirubin &gt; 2 mg/dL GPT &gt; 2 time normal value . Creatinine &gt; 2 mg/dL . Hypersensibility agent use protocol . Secondary MDS chemoradiotherapy . HIV positive . Chronic myeloblastic leukemia</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Peripheral blood stem cell transplantation</keyword>
	<keyword>Bone marrow transplantation</keyword>
	<keyword>Secondary Acute Myeloblastic Leukemia</keyword>
</DOC>